Noble Financial restated their buy rating on shares of Agile Therapeutics (NASDAQ:AGRX) in a research report sent to investors on Wednesday, March 14th.
Several other analysts also recently weighed in on the company. HC Wainwright restated a buy rating and issued a $8.00 price target on shares of Agile Therapeutics in a research note on Tuesday, March 13th. Janney Montgomery Scott downgraded Agile Therapeutics from a buy rating to a neutral rating in a research note on Thursday, December 28th. William Blair downgraded Agile Therapeutics from an outperform rating to a market perform rating in a research note on Tuesday, December 26th. Finally, Cantor Fitzgerald restated a buy rating and issued a $5.00 price target on shares of Agile Therapeutics in a research note on Friday, December 22nd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the stock. Agile Therapeutics has a consensus rating of Hold and an average target price of $9.00.
AGRX stock traded down $0.09 during trading on Wednesday, hitting $2.67. 132,340 shares of the company traded hands, compared to its average volume of 151,911. The stock has a market capitalization of $94.53, a PE ratio of -2.93 and a beta of 2.13. Agile Therapeutics has a 1 year low of $1.93 and a 1 year high of $5.60.
Agile Therapeutics (NASDAQ:AGRX) last announced its earnings results on Monday, March 12th. The specialty pharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.05. research analysts anticipate that Agile Therapeutics will post -0.71 EPS for the current fiscal year.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Perceptive Advisors LLC purchased a new stake in Agile Therapeutics during the 4th quarter valued at $9,092,000. Franklin Resources Inc. boosted its stake in Agile Therapeutics by 3.4% during the 4th quarter. Franklin Resources Inc. now owns 2,867,800 shares of the specialty pharmaceutical company’s stock valued at $7,714,000 after purchasing an additional 95,600 shares during the last quarter. Caxton Corp boosted its stake in Agile Therapeutics by 12.1% during the 3rd quarter. Caxton Corp now owns 1,820,012 shares of the specialty pharmaceutical company’s stock valued at $8,117,000 after purchasing an additional 196,445 shares during the last quarter. Alyeska Investment Group L.P. purchased a new stake in Agile Therapeutics during the 3rd quarter valued at $3,747,000. Finally, Renaissance Technologies LLC boosted its stake in Agile Therapeutics by 313.7% during the 4th quarter. Renaissance Technologies LLC now owns 366,100 shares of the specialty pharmaceutical company’s stock valued at $985,000 after purchasing an additional 277,600 shares during the last quarter. Institutional investors and hedge funds own 71.03% of the company’s stock.
TRADEMARK VIOLATION WARNING: This story was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/07/agile-therapeutics-agrx-stock-rating-reaffirmed-by-noble-financial.html.
Agile Therapeutics Company Profile
Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed Phase III clinical trials.
Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.